Stay updated on Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial page
- Check2 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check9 days agoChange DetectedAdded Melanoma as a topic and linked related topics, including MedlinePlus Genetics.SummaryDifference0.2%

- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedAdded Revision: v3.4.2; removed the lapse-in-funding notice and the government operating status update, and removed Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check37 days agoChange DetectedAdded a site-wide notice about the lapse in government funding and open status, and updated the page revision to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check44 days agoChange DetectedShow glossary has been added, and several metadata labels were updated (Last Update Submitted that Met QC Criteria; No FEAR Act Data; Revision: v3.4.0). Related topics and legacy labels (e.g., Melanoma, MedlinePlus Genetics, No FEAR Act data, Revision: v3.3.4) were removed.SummaryDifference0.4%

- Check51 days agoChange DetectedAdded Melanoma as a related topic and a MedlinePlus Genetics link as related topics on the study page.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial page.